개에서 재조합 과립구 자극 인자 (rh G-CSF)의 투여 간격에 따른 말초혈액과 골수의 반응에 대한 연구 A Study of Peripheral Blood and Bone Marrow Responses Depends on the Frequency of rhG-CSF Administration in Dogs원문보기
본 연구는 사람 재조합과립구자극인자 (rhG-CSF) 투여 간격에 따른 말초혈액과 골수의 변화를 평가하였다. 사람 재조합과립구자극인자는 개에서 항암치료 후 나타나는 골수억압 등에서 유용한 치료효과가 있는 것으로 알려져 있으나 그 투여간격에 따른 연구는 아직 진행되지 않았다. 따라서 본 연구에서는 다음과 같은 간격으로 실험 기간 동안 각각 2마리씩 3그룹으로 체중당 $5{\mu}g$으로 사람 재조합과립구자극인자를 주사하였다; (1) 하루에 한번 주사; 그룹 1, (2) 2일에 한번 주사; 그룹 2, (3) 3일에 한번 주사; 그룹 3, 말초혈액 분석과 100개의 직접 현미경 세포계수는 매일 실시하였다. 골수천자는 0일차, 3일차 9일차 마지막으로 말초혈액상 총 백혈구수가 정상범위내로 떨어지는 12일차 혹은 13일차에 시행하였다. 사람 재조합과립구자극인자는 모든 실험견에서 잘 투여되었으며 부작용을 보이지 않았다. 이러한 본 연구의 결과에 따르면 체중당 $5{\mu}g$의 사람 재조합과립구자극인자의 투여는 말초혈액과 골수에서 세포특이적이고 투여간격에 대체적으로 비례하는 효과를 보였으며 사람 재조합과립구자극인자 투여가 반복될수록 그 효과는 증가하였으며 사람 재조합과립구자극인자 투여를 중지한 이후에도 골수에 미치는 효과는 3일이상 지속되는 것으로 보여졌다. 따라서 본 연구의 결과를 통해 임상가들은 적절한 치료 간격을 세울 수 있을 것으로 기대된다.
본 연구는 사람 재조합과립구자극인자 (rhG-CSF) 투여 간격에 따른 말초혈액과 골수의 변화를 평가하였다. 사람 재조합과립구자극인자는 개에서 항암치료 후 나타나는 골수억압 등에서 유용한 치료효과가 있는 것으로 알려져 있으나 그 투여간격에 따른 연구는 아직 진행되지 않았다. 따라서 본 연구에서는 다음과 같은 간격으로 실험 기간 동안 각각 2마리씩 3그룹으로 체중당 $5{\mu}g$으로 사람 재조합과립구자극인자를 주사하였다; (1) 하루에 한번 주사; 그룹 1, (2) 2일에 한번 주사; 그룹 2, (3) 3일에 한번 주사; 그룹 3, 말초혈액 분석과 100개의 직접 현미경 세포계수는 매일 실시하였다. 골수천자는 0일차, 3일차 9일차 마지막으로 말초혈액상 총 백혈구수가 정상범위내로 떨어지는 12일차 혹은 13일차에 시행하였다. 사람 재조합과립구자극인자는 모든 실험견에서 잘 투여되었으며 부작용을 보이지 않았다. 이러한 본 연구의 결과에 따르면 체중당 $5{\mu}g$의 사람 재조합과립구자극인자의 투여는 말초혈액과 골수에서 세포특이적이고 투여간격에 대체적으로 비례하는 효과를 보였으며 사람 재조합과립구자극인자 투여가 반복될수록 그 효과는 증가하였으며 사람 재조합과립구자극인자 투여를 중지한 이후에도 골수에 미치는 효과는 3일이상 지속되는 것으로 보여졌다. 따라서 본 연구의 결과를 통해 임상가들은 적절한 치료 간격을 세울 수 있을 것으로 기대된다.
The present study evaluated that responses of peripheral and bone marrow depends on the frequency of recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration in dogs. The rhG-CSF has been revealed that have a beneficial effect for dogs with myelosuppression secondary to chemo...
The present study evaluated that responses of peripheral and bone marrow depends on the frequency of recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration in dogs. The rhG-CSF has been revealed that have a beneficial effect for dogs with myelosuppression secondary to chemotherapy or radiation but there were no studies about the frequency of administration in dogs. In this research, rhG-CSF was administrated $5{\mu}g/kg$ subcutaneously for each two-dogs group as follows: (1) every day for trial, (2) every other day for trial, (3) every third day for trial. The peripheral blood analysis including direct microscopic differential counts of one hundred cells was performed every day. Bone marrow aspiration was performed before administration of rh G-CSF, on the day of 0, 3, 9 and when the WBC counts were decreased within the normal range (day 12 or 13). Rh G-CSF was well-tolerated and showed no side effects in all dogs. According to the present study, $5{\mu}g/kg$ administration of rhG-CSF have cell-specific, frequency-related effect on bone marrow and peripheral blood. Furthermore, the effects of rhG-CSF administration on bone marrow sustained during the study and prolonged at least 3 days after discontinuing of rhG-CSF treatment.
The present study evaluated that responses of peripheral and bone marrow depends on the frequency of recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration in dogs. The rhG-CSF has been revealed that have a beneficial effect for dogs with myelosuppression secondary to chemotherapy or radiation but there were no studies about the frequency of administration in dogs. In this research, rhG-CSF was administrated $5{\mu}g/kg$ subcutaneously for each two-dogs group as follows: (1) every day for trial, (2) every other day for trial, (3) every third day for trial. The peripheral blood analysis including direct microscopic differential counts of one hundred cells was performed every day. Bone marrow aspiration was performed before administration of rh G-CSF, on the day of 0, 3, 9 and when the WBC counts were decreased within the normal range (day 12 or 13). Rh G-CSF was well-tolerated and showed no side effects in all dogs. According to the present study, $5{\mu}g/kg$ administration of rhG-CSF have cell-specific, frequency-related effect on bone marrow and peripheral blood. Furthermore, the effects of rhG-CSF administration on bone marrow sustained during the study and prolonged at least 3 days after discontinuing of rhG-CSF treatment.
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
가설 설정
Comparison among three groups of total leukocyte counts of dogs given 5 µg rhG-CSF/kg subcutaneously (A: Group 1, B: Group 2, C: Group 3). A: Daily administration of rhG-CSF leads to increase of total leukocyte count continuously. B: Leukocyte count of group 2 was not showed sustained increase but showed exceeding the established reference range (6000-17000/ µl).
B: Leukocyte count of group 2 was not showed sustained increase but showed exceeding the established reference range (6000-17000/ µl).
제안 방법
Before rh G-CSF administration, the samples were collected into EDTA-containing tubes, and complete blood cell counts analysis were performed between 5 and 8 p.m. using an automatic blood cell counter (Celltacα MEK-6450K, Nihon Kohden, Tokyo).
According to the present study, subcutaneous administration of rhG-CSF has cell-specific, frequency-dependent effects on bone marrow and peripheral blood, and the effects of rhG-CSF administration on bone marrow were sustained throughout the trial. Clinicians might be able to use the findings of this study to make suitable treatment regimens for patients with leukopenia.
The dogs were separated into three groups and rhGCSF was administered subcutaneously at a dose of 5 µg/kg to each group as follows: (1) every day for 10 days (10 times in total), (2) every other day for 11 days (six times in total), and (3) every third day for 10 days (four times in total).
Therefore, the purpose of the present report was to examine the hematologic changes that occur in response to different frequencies of rhG-CSF administration and the short-term effects of rhG-CSF administration on bone marrow in normal dogs.
대상 데이터
Six adult Beagles (mean weight 12.58 kg; three intact female dogs and three intact male dogs) were used in this study (Table 1). All dogs were housed in separate cages and regularly provided with commercial dry food and chlorinated tap water.
The rhG-CSF used in this study was prepared and provided by CJ Cheiljedang Corporation (Leukokine®, South Korea).
Prior to aspiration, dogs were sedated by intravenous injection of medetomidine (Domitor, Zoetis, Seoul). The sample was collected from both sides of the humerus and femur with a 13-gauge bone marrow biopsy needle (Medical Device Technologies INC, Angiotech, USA). The site was cleansed aseptically using povidone-iodine and alcohol.
이론/모형
0 program. The Kruskal-Wallis test and the Mann-Whitney U test were used to compare counts of leukocytes, granulocytes, eosinophils, lymphocytes, monocytes, and the M:E ratio of bone marrow among groups. For all analyses, a value of P < 0.
성능/효과
B: Leukocyte count of group 2 was not showed sustained increase but showed exceeding the established reference range (6000-17000/ µl). C: Total leukocyte of group 3 showed decreased within the normal range on the third day after G-CSF administration. *Reference range: 6,000-17,000/µl.
This report demonstrates that peripheral WBC counts increase significantly in dogs who receive daily rhG-CSF injections compared with dogs that receive injections every 2 days or every 3 days. Leukocytosis occurred within 24 hours of the first injection in all groups.
Twenty-four hours after rhG-CSF administration, WBC count of all dogs increased. The changes in WBC count results are shown in Fig 1.
참고문헌 (38)
Carulli G. Effects of recombinant human granulocyte colonystimulating factor administration on neutrophil phenotype and functions. Haematologica 1997; 82: 606-616.
Couto CG. Leukopenia and leukocytosis. In: Small animal internal medicine. 4th ed. St. Louis: Elsvier Mosby. 2009: 1228-1235.
Cullor JS, Smith W, Fairley N, Wood SL, Dellinger JD, Souza L. Effect of human granulocyte colony stimulating factor (HR-GCSF) on the hemogram of lactating dairy cattle. Vet Clin Pathol 1990; 19: 9-12.
Hammond WP, Csiba E, Canin A, Hockman H, Souza LM, Layton JE, Dale DC. Chronic neutropenia. A new canine model induced by human granulocyte colony-stimulating factor. J Clin Invest 1991; 87: 704-710.
Hasegawa T, Inomata T. Effect of recombinant human granulocyte colony stimulating factor on lymphocyte blastogenesis in healthy dogs. J Vet Med Sci 2000; 62: 1205-1207.
Henry CJ, Buss MS, Lothrop CD. Veterinary uses of recombinant human granulocyte colony-stimulating factor. I. Oncology. Compend Contin Educ Prac Vet 1998; 20: 728-735.
Ikebuchi K, Clark SC, Ihle JN, Souza LM, Ogawa M. Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci U S A 1988; 85: 3445-3449.
Jakubowski AA, Souza L, Kelly F, Fain K, Budman D, Clarkson B, Bonilla MA, Moore MA, Gabrilove J. Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropenia. N Engl J Med 1989; 320: 38-42.
Karawajczyk M, Hoglund M, Ericsson J, Venge P. Administration of G-CSF to healthy subjects: the effects on eosinophil counts and mobilization of eosinophil granule proteins. Br J Haematol 1997; 96: 259-265.
Kerst JM, De Haas M, Van Der Schoot C E, Slaper- Cortenbach ICM, Kleijer M, Von Dem Borne AEGKR, Van Oers RHJ. Recombinant granulocyte colony-stimulating factor administration to healthy volunteers : Induction of immunophenotypically and functionally altered neutrophils via an effects on myeloid progenitor cells. Blood 1993; 82: 3265-3272.
Lothrop CD Jr., Warren DJ, Souza LM, Jones JB, Moore MA. Correction of canine cyclic hematopoiesis with recombinant human granulocyte colony-stimulating factor. Blood 1988; 72: 1324-1328.
MacVittie TJ, Monroy RL, Patchen ML, Souza LM. Therapeutic use of recombinant human G-CSF (rhG-CSF) in a canine model of sublethal and lethal whole-body irradiation. Int J Radiat Biol 1990; 57: 723-736.
Mayer P, Werner FJ, Lam C, Besemer J. In vitro and in vivo activity of human recombinant granulocyte-macrophage colony-stimulating factor in dogs. Exp Hematol 1990; 18: 1026-1033.
Miller LL. Current status of G-CSF in support of chemotherapy and radiotherapy. Oncology 1993; 7: 67-83.
Mischke R, Barth T, Wohlsein P, Rohn K, Nolte I. Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on leukocyte count and survival rate of dogs with parvoviral enteritis. Res Vet Sci 2001; 70: 221-225.
Mishu L, Callahan G, Allebban Z, Maddux JM, Boone TC, Souza LM, Lothrop CD Jr. Effects of recombinant canine granulocyte colony-stimulating factor on white blood cell production in clinically normal and neutropenic dogs. J Am Vet Med Assoc 1992; 200: 1957-1964.
Morstyn G, Foote M, Lieschke GJ. Hematopoietic growth factors in cancer chemotherapy. Cancer Chemother Biol Response Modif 1996; 16: 295-314.
Obradovich JE, Ogilvie GK, Powers BE, Boone T. Evaluation of recombinant canine granulocyte colony-stimulating factor as an inducer of granulopoiesis. A pilot study. J Vet Intern Med 1991; 5: 75-79.
Ogilvie GK, Obradovich JE. Hematopoitic growth factors: clinical use and implications. In: Kirk's current veterinary therapy, 6th ed. London: WB Saunders Co. 1992: 466-470.
Rewerts JM, McCaw DL, Cohn LA, Wagner-Mann C, Harrington D. Recombinant human granulocyte colony-stimulating factor for treatment of puppies with neutropenia secondary to canine parvovirus infection. J Am Vet Med Assoc 1998; 213: 991-992.
Schuening FG, Storb R, Goehle S, Graham TC, Appelbaum FR, Hackman R, Souza LM. 1989. Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation. Blood 1989; 74: 1308-1313.
Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE, Henney C, Gutterman JU. Effects of recombinant human granulocytemacrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1987; 317: 1545.
Weaver CH, Longin K, Buckner CD, Bensinger W. Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 1994; 13: 411-415.
Welte K, Bonilla MA, Gillio AP, Boone TC, Potter GK, Gabrilove JL, Moore MA, O'Reilly RJ, Souza LM. Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 1987; 165: 941-948.
Yakushijin Y, Shikata H, Takaoka I, Horikawa T, Takeuchi K, Yamanouchi J, Azuma T, Narumi H, Hato T, Yasukawa M. Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy. Int J Clin Oncol 2011; 16: 118-124.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.